Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy
- PMID: 35366506
- PMCID: PMC8976143
- DOI: 10.1016/j.breast.2022.03.008
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy
Abstract
Aim: Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications for post-mastectomy radiation therapy (PMRT) have broadened. The aim of the Oncoplastic Breast Consortium initiative was to address relevant questions arising with this clinically challenging scenario.
Methods: A large global panel of oncologic, oncoplastic and reconstructive breast surgeons, patient advocates and radiation oncologists developed recommendations for clinical practice in an iterative process based on the principles of Delphi methodology.
Results: The panel agreed that surgical technique for NSM/SSM should not be formally modified when PMRT is planned with preference for autologous over implant-based BR due to lower risk of long-term complications and support for immediate and delayed-immediate reconstructive approaches. Nevertheless, it was strongly believed that PMRT is not an absolute contraindication for implant-based or other types of BR, but no specific recommendations regarding implant positioning, use of mesh or timing were made due to absence of high-quality evidence. The panel endorsed use of patient-reported outcomes in clinical practice. It was acknowledged that the shape and size of reconstructed breasts can hinder radiotherapy planning and attention to details of PMRT techniques is important in determining aesthetic outcomes after immediate BR.
Conclusions: The panel endorsed the need for prospective, ideally randomised phase III studies and for surgical and radiation oncology teams to work together for determination of optimal sequencing and techniques for PMRT for each patient in the context of BR.
Keywords: Autologous breast reconstruction; Breast cancer; Implant-based breast reconstruction; Nipple-sparing mastectomy; Post-mastectomy radiotherapy.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
No competing interests in the current work were reported. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:
F. Brenelli had personal honoraria for Roche, MSD and Zodiac.
P. Dubsky received other from Amgen, AstraZeneca, Pfizer, Roche and Merck, grants from Cepheid/Danaher, Agendia, Myriad and from Oncomark.
M. Gnant reports personal fees/travel support from Amgen, DaiichiSankyo, AstraZeneca, EliLilly, LifeBrain, Nanostring, Novartis; an immediate family member is employed by Sandoz.
Support for meetings and teaching tasks has been paid to the research Department directed by Y. Harder from Establishment Labs, S.A, Costa Rica, Integra Life Sciences, USA and Hilotherm GmbH, Germany.
S Kuemmel has minority non-profit ownership at WSG Study Group; has a consulting/advisory board role at Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Seagen. Pfizer, pfm Medical, Roche, Somatex, Seagen, Hologic; and received fees from Roche, Somatex, Novartis, Lilly, and personal fees from Roche, Novartis and Hologic.
Ch. Kurzeder receives honoraria from Tesaro, GSK, Astra Zeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A, Pfizer, Daichi, and travel fees from GSK, Astra Zeneca, Roche. He has a consulting or advisory role for Tesaro, GSK, Astra Zeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A, Merck MSD, Pfizer.
Travel, Accommodations, Expenses: GSK, Astra Zeneca, Roche.
A. Pusic is a co-developer of the BREAST-Q and receives royalties when it is used in for-profit, industry-sponsored clinical trials.
M. Walker has received personal honoraria from Guerbet and Roche Products Pty Ltd.
W. P. Weber received research from Takeda Pharmaceuticals International paid to the Swiss Group for Clinical Cancer Research (SAKK) and personal honoraria from Genomic Health, Inc, USA. for meetings was paid to his institution from Sandoz, Genomic Health, Medtronic Medtronic, Novartis Oncology, Pfizer and Eli Lilly.
S. Formenti reports: Consultant for: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, Merck US, EMD Serono/Merck, Genentech/ROCHE, Boheringer, Accuray.
Grant/Research support from: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex, ArcusM.Morrow reports personal fees from Exact Sciences and Roche.
All other authors declare no competing interests.
Figures











References
-
- Kummerow K.L., Du L., Penson D.F., et al. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9–16. - PubMed
-
- Sisco M., Kyrillos A.M., Lapin B.R., et al. Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States. Breast Cancer Res Treat. 2016;160:111–120. - PubMed
-
- Poortmans P.M., Collette S., Kirkove C., et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317–327. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical